Cargando…

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas

PURPOSE: Carbapenem-resistant Enterobacterales (CRE) are subject to intense global monitoring in an attempt to maintain awareness of prevalent and emerging resistance mechanisms and to inform treatment and infection prevention strategies. CRE and extended-spectrum beta-lactamase (ESBL)-producing Ent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parker, Jennifer K, Gu, Richard, Estrera, Gregory A, Kirkpatrick, Betsy, Rose, Dusten T, Mavridou, Despoina A I, Mondy, Kristin E, Davies, Bryan W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987243/ https://www.ncbi.nlm.nih.gov/pubmed/36891378 http://dx.doi.org/10.2147/IDR.S403448

Ejemplares similares

Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas
por: Black, Cody A., et al.
Publicado: (2021)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
por: Bandy, Altaf, et al.
Publicado: (2021)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Carbapenem-Sparing Strategies for ESBL Producers: When and How
por: Karaiskos, Ilias, et al.
Publicado: (2020)

Occurrence, Typing, and Resistance Genes of ESBL/AmpC-Producing Enterobacterales in Fresh Vegetables Purchased in Central Israel
por: Kon, Hadas, et al.
Publicado: (2023)

1199. Effectiveness of Non-carbapenem vs Carbapenems Empiric Therapy for Extended-Spectrum β-Lactamase (ESBL)-producing Enterobacterales (PE) Infections in Non-ICU patients: A Real-world Investigation in a Hospital with High-prevalence of ESBL-PE
por: Kang, Amy Y, et al.
Publicado: (2023)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales
por: Takei, Kentarou, et al.
Publicado: (2023)

Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland
por: Kuch, Alicja, et al.
Publicado: (2020)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

The Impact of COVID-19 Pandemic on ESBL-Producing Enterobacterales Infections: A Scoping Review
por: Mai, Ha Thi Thao, et al.
Publicado: (2023)

Cryptococcus neoformans blood stream infection in severe COVID-19 pneumonia
por: Thyagarajan, Rama. V, et al.
Publicado: (2021)

Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017–2019
por: Wielders, Cornelia C. H., et al.
Publicado: (2022)

Monitoring of Non-β-Lactam Antibiotic Resistance-Associated Genes in ESBL Producing Enterobacterales Isolates
por: Shinu, Pottathil, et al.
Publicado: (2020)

Carriage of ESBL-producing Enterobacterales in wastewater treatment plant workers and surrounding residents — the AWARE Study
por: Rodríguez-Molina, Daloha, et al.
Publicado: (2021)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Detection of Multidrug-Resistant Enterobacterales—From ESBLs to Carbapenemases
por: Noster, Janina, et al.
Publicado: (2021)

Acute Chagas Disease Manifesting as Orbital Cellulitis, Texas, USA
por: Hudson, F. Parker, et al.
Publicado: (2021)

Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales
por: Lim, Fang Kang, et al.
Publicado: (2020)

Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales
por: Ávila-Núñez, M., et al.
Publicado: (2023)

Clinical epidemiology of carbapenem-resistant Enterobacterales in the Greater Houston region of Texas: a 6-year trend and surveillance analysis
por: Tadese, Bekana K., et al.
Publicado: (2022)

Prevalence of ESBL, AmpC and Carbapenemase-Producing Enterobacterales Isolated from Raw Vegetables Retailed in Romania
por: Colosi, Ioana Alina, et al.
Publicado: (2020)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

197. The Clinical Impact of Early Detection of ESBL-Producing Enterobacterales with PCR-Based Blood Culture Assays
por: Chang, Kai-Ming, et al.
Publicado: (2022)

CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
por: Mathers, Amy J, et al.
Publicado: (2021)

1706. Risk factors for infections caused by extended spectrum beta lactamase (ESBL) producing and Carbapenem-resistant Enterobacterales (CRE) in pediatric critical care settings: A case control study
por: Omar, Amr, et al.
Publicado: (2023)

Risk factors for predicting extended-spectrum β-lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates
por: Burgoon, Rachel, et al.
Publicado: (2023)

Analysis of Extended Spectrum Beta Lactamase (ESBL) Genes of Non-Invasive ESBL Enterobacterales in Southeast Austria in 2017
por: Paulitsch-Fuchs, Astrid H., et al.
Publicado: (2022)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Updates on the Status of Carbapenem-Resistant Enterobacterales in Lebanon
por: Fadlallah, Mahdi, et al.
Publicado: (2023)

Prolonged carriage of ESBL-producing enterobacterales and potential cross-transmission among residents in geriatric long-term care facilities
por: Ae, Ryusuke, et al.
Publicado: (2021)

Antimicrobial susceptibility testing profiles of ESBL-producing Enterobacterales isolated from hospital and community adult patients in Blantyre, Malawi
por: Onduru, Onduru G., et al.
Publicado: (2021)

Detection of Extended-Spectrum β-Lactamases (ESBLs) and AmpC in Class A and Class B Carbapenemase-Producing Enterobacterales
por: Imkamp, Frank, et al.
Publicado: (2022)

Spatiotemporal dissemination of ESBL-producing Enterobacterales in municipal sewer systems: a prospective, longitudinal study in the city of Basel, Switzerland
por: Gómez-Sanz, Elena, et al.
Publicado: (2023)

1153. ESBL Producing E. coli Urinary Tract Infections in Children: Is Carbapenem Always Necessary?
por: del Carmen, Ruiz Cabrales Diva, et al.
Publicado: (2021)

2826. Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing Enterobacterales and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)
por: Fernandez, Maria, et al.
Publicado: (2023)

185. Does an Infectious Diseases Consultation Improve Clinical Outcomes and Treatment Bundle Adherence for Enterococcal Bacteremia in a Multicenter Healthcare System?
por: Shephard, Emily A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2elb1io67bmlkt0ir3qnhfoe9c